Pactiv Evergreen (PTVE) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Announced sale of Pine Bluff and Waynesville facilities for $110 million, marking exit from paper mills and focus on North American converting operations; expected to close in Q4 2024.
Q2 2024 net income was $20 million, reversing a $139 million loss last year, driven by higher gross profit and lower restructuring charges.
Q2 results impacted by weak consumer demand, increased price sensitivity, and operational disruptions at Pine Bluff.
Strategic cost actions and headcount reductions planned to reduce operating costs by $15 million in 2024.
Revised 2024 guidance downward due to slower demand recovery and pending divestitures.
Financial highlights
Q2 net revenues: $1,338 million, down 6% year-over-year but up 7% sequentially.
Adjusted EBITDA: $183 million, down 16% year-over-year, up 9% sequentially; margin at 14%.
Free cash flow: $37 million, down 50% year-over-year, improved from negative $74 million in Q1.
Gross profit increased 165% to $223 million, with gross margin rising to 17% from 6% year-over-year.
Net cash provided by operating activities was $94 million in Q2 2024.
Outlook and guidance
Full-year 2024 Adjusted EBITDA guidance revised to $800–$820 million (prior: $850–$870 million).
Capital expenditures expected at $260 million, down from $300 million.
Free cash flow guidance: $180–$200 million (prior: $200 million+).
Anticipate ending 2024 with net leverage ratio of ~4x.
Sale of Pine Bluff and Waynesville expected to close in Q4 2024; guidance includes expected non-cash impairment charges of $320–$340 million in Q3.
Latest events from Pactiv Evergreen
- Transformation drives growth through innovation, cost savings, and strategic channel focus.PTVE
Jefferies Global Industrial Conference 202422 Jan 2026 - Q3 net loss of $213M on $1.33B revenue; $322M impairment drives updated 2024 guidance.PTVE
Q3 202414 Jan 2026 - Net loss narrowed on lower revenues as Pactiv Evergreen restructures ahead of Novolex merger.PTVE
Q4 20249 Jun 2025